论文部分内容阅读
目的探讨α_1受体阻滞剂治疗男性神经原性逼尿肌尿道外括约肌功能失调(NDSD)的疗效和安全性。方法 100例NDSD患者,随机分为对照组(47例)和观察组(53例),对照组给予安慰剂治疗,观察组给予α_1受体阻滞剂(盐酸坦索罗辛缓释胶囊)治疗。比较两组患者治疗前后间歇导尿(IC)例数、膀胱剩余尿量(PVR)、泌尿生殖系困扰调查的6项短表(UDI-6)、最大尿流率(Qmax)、最大尿流率时膀胱逼尿肌压力(Pdet.Qmax)、最大尿道闭合压力(MUCP)及不良反应发生情况。结果观察组治疗12周后UDI-6、PVR、IC例数、Qmax、Pdet.Qmax、MUCP均优于对照组(P<0.05)。观察组不良反应发生率(1.89%)与对照组(4.26%)对比,差异无统计学意义(P>0.05)。结论 NDSD患者采用α_1受体阻滞剂治疗,能有效改善自身机体排尿障碍,提高患者生活质量,值得临床推广。
Objective To investigate the efficacy and safety of α_1 receptor antagonist in the treatment of male neurogenic detrusor external sphincter dysfunction (NDSD). Methods 100 patients with NDSD were randomly divided into control group (n = 47) and observation group (n = 53). The control group was given placebo and the observation group was treated with α_1 blocker (tamsulosin hydrochloride sustained-release capsule) . Six short-term tables (UDI-6), maximum flow rate (Qmax), maximum flow rate (Qmax), number of intermittent catheterisation (ICD), residual bladder volume (PVR) and genitourinary disturbance were compared between the two groups before and after treatment Rate of detrusor pressure (Pdet.Qmax), maximum urethral closure pressure (MUCP) and adverse reactions. Results After treatment for 12 weeks, UDI-6, PVR, IC cases, Qmax, Pdet.Qmax and MUCP in observation group were better than those in control group (P <0.05). The incidence of adverse reactions in the observation group (1.89%) was not significantly different from that in the control group (4.26%) (P> 0.05). Conclusion NIDD patients treated with α_1 blockers can effectively improve their body dysuria and improve the quality of life of patients, worthy of clinical promotion.